… 1/2 InSight extension study to be reported in H2 2021 QR-421a Stellar Phase 1/2 trial for Usher syndrome and … progress anticipated with first clinical data in 2021 from QR-1123 program for autosomal dominant retinitis pigmentosa and QR-504a clinical study in Fuchs endothelial corneal dystrophy …
… study to be reported in H2 2021 Enrollment completed for QR-421a dosing cohorts and data from next Phase 1/2 interim … expected in H1 2021 Initial data from Phase 1/2 trial of QR-1123 expected in 2021 QR-504a clinical study in Fuchs expected to start in H1 2021 …
… of sepofarsen for Leber Congenital Amaurosis 10 (LCA10), QR-421a for Usher syndrome and non-syndromic retinitis pigmentosa (nsRP), and QR-1123 for autosomal dominant retinitis pigmentosa (adRP) … trial is ongoing with initial data on track for 2021. QR-504a for Fuchs Endothelial Corneal Dystrophy (FECD): All …
… sepofarsen for CEP290 -mediated LCA10 on track for H1 2022 QR-421a pivotal Sirius and Celeste Phase 2/3 trials in Usher … 2021 Initial clinical data from Phase 1/2 Aurora trial of QR-1123 for autosomal dominant retinitis pigmentosa expected … our fourth pipeline program for a genetic eye disease, QR-504a for Fuchs endothelial corneal dystrophy.” Business …
… 2/3 Sirius and Celeste clinical trials of ultevursen (QR-421a) in Usher syndrome and retinitis pigmentosa underway; … planned by year-end 2022 Repeated dose study planned for QR-1123 for autosomal dominant retinitis pigmentosa and … from molecular proof-of concept biomarker study for QR-504a for Fuchs endothelial corneal dystrophy to be reported …
… trial getting underway and expected to enroll 10 patients. QR-421a for USH2A -mediated Usher syndrome and retinitis … tomography (OCT) retinal imaging, after a single dose of QR-421a. QR-421a was observed to be well tolerated with no … dose P hase 2 trial with doses up to 300 μg in 2022. QR-504a for TCF4 -mediated Fuchs Endothelial Corneal Dystrophy …
… upfront and equity and up to $1.25 billion in milestones QR-421a Phase 2/3 Sirius and Celeste trials in Usher syndrome … as anticipated. We expect to start two Phase 2/3 trials of QR-421a in Usher syndrome and nsRP before the end of the … an update from our QR-1123 program in adRP and our QR-504a Fuchs Focus trial is open for enrollment, representing …
… data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic … trial of sepofarsen, reporting positive clinical data for QR-421a, and strengthening our financial position with a … for LCA10. Our fourth ophthalmology pipeline program, QR-504a for Fuchs endothelial corneal dystrophy, is expected to …
… interim analysis findings from Phase 1/2 Stellar trial of QR-421a for Usher syndrome and non-syndromic retinitis … the interim analysis of the Phase 1/2 Stellar trial of QR-421a for Usher’s syndrome, which adds to the growing body … trial is ongoing with initial data on track for 2021. QR-504a for Fuchs Endothelial Corneal Dystrophy (FECD): QR-504a …
Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate initiated with data expected in H1 2021Phase 1/2 Stellar